AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34083236
Drug: CX-2029 at
RxNorm normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-2029 at 4 mg/kg (expanded cohort)
Trial: 34083421
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously on days 1 and 15, with surgery planned by day 29.
Trial: 34083618
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg/day for 15 weeks
Trial: 34084608
Drug: Neurotechnology-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotechnology-based therapy (seizure advisory system)
Trial: 34085287
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo, no treatment, or conventional therapies)
Trial: 34085900
Drug: MenACYW-TT booster
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACYW-TT booster dose
Trial: 34086171
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel 80 mg/m² with carboplatin, trastuzumab, and pertuzumab (wPCbTP)
Trial: 38112922
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg, twice daily)
Trial: 34087943
Drug: Radiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation with concurrent platinum-based chemotherapy
Trial: 34087967
Drug: Other (TMG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other (TMG, implant)
Trial: 34088733
Drug: Perioperative iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative iron administration
Trial: 34089650
Drug: Nusinersen (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen (6 mg equivalent for cohort 1, 12 mg for cohort 2)
Trial: 34089650
Drug: Nusinersen (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen (12 mg)
Trial: 34089751
Drug: Preoperative stereotactic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative stereotactic ablative body radiotherapy (SBRT) as 5 fractions of 7 Gy with dose reduction to 5 fractions of 5 Gy on tumor margins.
Trial: 34090525
Drug: Training +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training + implementation enhanced resources (including a champion at each site and monthly peer support consultation calls)
Trial: 34090865
Drug: Nanotechnology-based strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanotechnology-based strategies for cancer diagnosis and therapy
Trial: 34092158
Drug: Pregabalin pharmacotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin pharmacotherapy, dosage and duration not available
Trial: 34092233
Drug: Rigosertib (RGS)
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigosertib (RGS) monotherapy (300 mg/kg)
Trial: 34092233
Drug: Rigosertib (RGS)
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigosertib (RGS) in combination with αPD1 + αCTLA4
Trial: 34092549
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of subanesthetic intravenous ketamine and therapist-administered e-CBT over 14 weeks
Trial: 34092549
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control group receiving the experimental treatment after 14 weeks
Trial: 34093444
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (median dose of 50 μg)
Trial: 34094549
Drug: Medium and
RxNorm normalized name: blood pressure test kit medium and large cuffs MISCELL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium and long treatment regimens of low-dose IL-2
Trial: 34094549
Drug: Long treatment
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long treatment regimen of low-dose IL-2
Trial: 34095161
Drug: Electroacupuncture therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture therapy, details on dosage and duration not available
Trial: 34095178
Drug: Multimodal prehabilitation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal prehabilitation, details on dosage and duration not available
Trial: 34096037
Drug: Rectal water-contrast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal water-contrast transvaginal ultrasonography (RWC-TVS)
Trial: 34096690
Drug: Sotorasib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotorasib (960 mg orally once daily)
Trial: 34097071
Drug: Dexamethasone-corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone-corticotropin-releasing hormone (Dex/CRH) test
Trial: 34097100
Drug: Trifluridine/tipiracil (FTD/TPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil (FTD/TPI) at a dose of 35 mg/m²
Trial: 34098895
Drug: K-001 (1350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-001 (1350 mg to 2160 mg, administered twice daily in four-week cycles)
Trial: 34098967
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without treatment limitation
Trial: 34098967
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with any treatment limitation
Trial: 34098967
Drug: Treatment limitations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment limitations (PTL)
Trial: 34099518
Drug: Tubeless, on-body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubeless, on-body automated insulin delivery system with customizable glycemic targets
Trial: 34099518
Drug: Usual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual insulin regimen (2-week standard therapy phase)
Trial: 34099718
Drug: neoadjuvant eribulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant eribulin therapy
Trial: 34099953
Drug: Manual lymphatic
RxNorm normalized name: PINPOINT Lymphatics Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymphatic drainage treatment
Trial: 34100024
Drug: Virus-targeted treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-targeted treatment and prevention strategies
Trial: 34101090
Drug: RNA-pulsed dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA-pulsed dendritic cell vaccines
Trial: 34101090
Drug: RNA-loaded nanoparticle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA-loaded nanoparticle vaccines
Trial: 34103352
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (dMMR cohort)
Trial: 34103352
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (pMMR cohort)
Trial: 34104849
Drug: Combined EPA+DHA
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined EPA+DHA intake (median daily intake 70 mg, IQR: 32, 145 mg)
Trial: 34104878
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (CP) therapy, transfusion in three doses of 3 mL/kg of recipient body weight at 2-day intervals
Trial: 34105312
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination plan (DMARD and biologic started together)
Trial: 34105312
Drug: Step-up plan
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up plan (initial nonbiologic DMARD monotherapy)
Trial: 34105312
Drug: Biologic first
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic first plan (biologic monotherapy)
Trial: 34105312
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination plan
Trial: 34105902
Drug: Inpatient trauma
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient trauma treatment
Trial: 34107166
Drug: Napabucasin (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napabucasin (240 mg twice daily; days 1-11)
Trial: 34107771
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy
Trial: 34107914
Drug: Simulation-based nursing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation-based nursing intervention including usual care, an informational booklet from NCI, and three meetings with a nurse interventionist during radiation treatment followed by a booster call two weeks posttreatment.
Trial: 34108168
Drug: IA injection
RxNorm normalized name: factor VIIa Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA injection of triamcinolone acetonide
Trial: 34109185
Drug: Pre-operative/Neoadjuvant Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative/Neoadjuvant Therapy and Vascular Debranching followed by Resection
Trial: 34109306
Drug: C-IVIG (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IVIG (0.15 g/kg)
Trial: 34109306
Drug: C-IVIG (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IVIG (0.20 g/kg)
Trial: 34109306
Drug: C-IVIG (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IVIG (0.25 g/kg)
Trial: 34109306
Drug: C-IVIG (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IVIG (0.30 g/kg)
Trial: 34109306
Drug: C-IVIG (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-IVIG (all dosage arms)
Trial: 34109484
Drug: FCN-437c 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 50 mg
Trial: 34109484
Drug: FCN-437c 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 100 mg
Trial: 34109484
Drug: FCN-437c 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 200 mg
Trial: 39188943
Drug: FCN-437c 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 300 mg
Trial: 34109484
Drug: FCN-437c 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c 450 mg
Trial: 34109484
Drug: FCN-437c (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-437c (all doses)
Trial: 34109515
Drug: WBRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRT + sorafenib (200 mg daily for 21 days)
Trial: 34109624
Drug: HC-1119 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC-1119 at doses of 40, 80, 160, and 200 mg/day (part A)
Trial: 34109624
Drug: HC-1119 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HC-1119 at doses of 80 and 160 mg (part B)
Trial: 34110383
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg/d for 3 cycles) followed by combination with venetoclax (ramp-up to 400 mg/d for 24 cycles)
Trial: 34110489
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for progressive well-differentiated NETs
Trial: 34111887
Drug: Prior use
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior use of systemic or topical fluorescein
Trial: 34112454
Drug: PREDICT-TAVR score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PREDICT-TAVR score (6-item score including blood hemoglobin, serum iron concentrations, oral anticoagulation, dual antiplatelet therapy, common femoral artery diameter, and creatinine clearance)
Trial: 34112707
Drug: Sulindac 150
RxNorm normalized name: sulindac 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 150 mg twice daily for 12 months
Trial: 34113254
Drug: Qingre Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Huoxue treatment (QRHXD/QRHXEP)
Trial: 34113571
Drug: Chemo or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo or targeted therapy alone
Trial: 34115136
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy for SCD with nonmyeloablative conditioning and related haploidentical donors
Trial: 34115136
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy for SCD
Trial: 34115136
Drug: Busulfan treatment
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan treatment
Trial: 34115607
Drug: Surveys administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surveys administered through the Roadmap 2.0 app
Trial: 34116329
Drug: ICS (Inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS (Inhaled Corticosteroids)
Trial: 34116329
Drug: LABA +
RxNorm normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA + ICS (Long-Acting Beta-Agonists + Inhaled Corticosteroids)
Trial: 34116329
Drug: LABA +
RxNorm normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA + LAMA (Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists)
Trial: 34116329
Drug: LABA +
RxNorm normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA + LAMA + ICS (Triple therapy)
Trial: 34116329
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (never used ICS, LABA + ICS, LABA + LAMA, or triple therapy)
Trial: 34116533
Drug: Capecitabine or
RxNorm normalized name: capecitabine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine or 5-fluorouracil in combination with oxaliplatin or irinotecan
Trial: 34116645
Drug: Oral anti-diabetic
RxNorm normalized name: Diabetic Tussin EX Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-diabetic therapies
Trial: 34116645
Drug: Anti-hypertensive therapies
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive therapies
Trial: 34116645
Drug: Lipid-lowering therapies
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapies
Trial: 34116645
Drug: Insulin therapies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapies
Trial: 34116645
Drug: HbA1c treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HbA1c treatment target not achieved (HbA1c ≥ 7.0%)
Trial: 34116645
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure treatment target not achieved (BP ≥ 140/90 mmHg)
Trial: 34116645
Drug: LDL-cholesterol treatment
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-cholesterol treatment target not achieved (LDL-cholesterol ≥ 2.6 mmol/L)
Trial: 34116699
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of antidepressants at the clinic
Trial: 34116727
Drug: ABLE intervention
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABLE intervention (8-week home-based occupational therapy program)
Trial: 34117077
Drug: Mineralocorticoid Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid Receptor Antagonists
Trial: 34117380
Drug: 0.2 μg/day fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/day fluocinolone acetonide implant (FAi)
Trial: 34117601
Drug: Physical functional
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical functional capacity measured by daily home accelerometry for IPF
Trial: 34117737
Drug: i.v. methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. methylprednisolone (500 mg for 3 consecutive days, total of 1500 mg) followed by i.v. Tocilizumab (8 mg/kg) on day 3 and thereafter weekly s.c. Tocilizumab injections (162 mg) over 52 weeks
Trial: 34117737
Drug: Glucocorticoid pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid pulse therapy
Trial: 34117759
Drug: Increased X-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased X- and Y-chromosome dosage
Trial: 34118018
Drug: Transdermal 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 2% testosterone gel 300 mcg/day (T group)
Trial: 34118018
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (T + E group)
Trial: 34118198
Drug: Pralsetinib 400
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pralsetinib 400 mg once-daily oral treatment
Trial: 34118361
Drug: AWRK6 synthetic
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AWRK6 synthetic peptide via intraperitoneal injection
Trial: 34118361
Drug: AWRK6 synthetic
RxNorm normalized name: Camphor (synthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AWRK6 synthetic peptide in insulin-induced HepG2 cells
Trial: 34118856
Drug: Care of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care of the Dying Evaluation - Emergency Medicine questionnaire
Trial: 34118944
Drug: Chloroquine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (750 mg)
Trial: 34120214
Drug: Autologous antigen-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous antigen-specific T-cells (Melan-A and MELOE-1) with subcutaneous IL-2
Trial: 34120312
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg QD
Trial: 34122611
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine
Trial: 39739907
Drug: Nilotinib 300
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300 mg twice-daily
Trial: 38104036
Drug: Treatment-free remission
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free remission (TFR)
Trial: 34124106
Drug: Sleep-disordered breathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-disordered breathing treatment, specific intervention details not available
Trial: 34124111
Drug: Patient-Controlled Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Intravenous Analgesia with Tramadol
Trial: 34124781
Drug: Nephrotoxic serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrotoxic serum (NTS) administered on day 14 after EAV induction.
Trial: 34124781
Drug: Small molecule
RxNorm normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule kinase inhibitor (fostamatinib) administered over a 4-day treatment period.
Trial: 34124781
Drug: Control protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control protein (not MPO) administered instead of MPO.
Trial: 34125405
Drug: Glecaprevir/pibrentasvir (8-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (8-week treatment)
Trial: 34126109
Drug: ALXN1830 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1830 (10 mg/kg) administered as five weekly intravenous doses
Trial: 34126262
Drug: PF-06480605 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06480605 (500 mg intravenous every 2 weeks, 7 doses total)
Trial: 34126756
Drug: Cardioprotective medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioprotective medications
Trial: 34126939
Drug: TAF (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF (25 mg/d)
Trial: 34126939
Drug: TDF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF (300 mg/d)